These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1257 related articles for article (PubMed ID: 15599989)
1. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis. Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989 [TBL] [Abstract][Full Text] [Related]
2. Tacrolimus ointment: new preparation. Too many unknowns. Prescrire Int; 2004 Jun; 13(71):86-9. PubMed ID: 15233141 [TBL] [Abstract][Full Text] [Related]
3. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150 [TBL] [Abstract][Full Text] [Related]
4. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179 [TBL] [Abstract][Full Text] [Related]
5. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Papp K; Staab D; Harper J; Potter P; Puig L; Ortonne JP; Molloy S; Barbier N; Paul C; Int J Dermatol; 2004 Dec; 43(12):978-83. PubMed ID: 15569038 [TBL] [Abstract][Full Text] [Related]
6. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis]. de Bruin-Weller MS; Bruijnzeel-Koomen CA Ned Tijdschr Geneeskd; 2005 May; 149(20):1096-100. PubMed ID: 15932135 [TBL] [Abstract][Full Text] [Related]
7. The role of topical calcineurin inhibitors in atopic dermatitis. Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K; Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171 [TBL] [Abstract][Full Text] [Related]
8. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. McKenna SP; Whalley D; de Prost Y; Staab D; Huels J; Paul CF; van Assche D J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):248-54. PubMed ID: 16503881 [TBL] [Abstract][Full Text] [Related]
9. Spotlight on topical pimecrolimus in pediatric atopic dermatitis. Yang LP; Curran MP Am J Clin Dermatol; 2010; 11(4):295-8. PubMed ID: 20509720 [TBL] [Abstract][Full Text] [Related]
10. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032 [TBL] [Abstract][Full Text] [Related]
11. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis. Hebert AA Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454 [TBL] [Abstract][Full Text] [Related]
12. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Ruer-Mulard M; Aberer W; Gunstone A; Kekki OM; López Estebaranz JL; Vertruyen A; Guettner A; Hultsch T Pediatr Dermatol; 2009; 26(5):551-8. PubMed ID: 19840309 [TBL] [Abstract][Full Text] [Related]
13. Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study. Kubota Y; Yoneda K; Nakai K; Katsuura J; Moriue T; Matsuoka Y; Miyamoto I; Ohya Y J Am Acad Dermatol; 2009 Feb; 60(2):212-7. PubMed ID: 19027990 [TBL] [Abstract][Full Text] [Related]
14. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. Zuberbier T; Bräutigam M J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):718-21. PubMed ID: 18312323 [TBL] [Abstract][Full Text] [Related]
16. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. Papp KA; Werfel T; Fölster-Holst R; Ortonne JP; Potter PC; de Prost Y; Davidson MJ; Barbier N; Goertz HP; Paul C J Am Acad Dermatol; 2005 Feb; 52(2):240-6. PubMed ID: 15692468 [TBL] [Abstract][Full Text] [Related]
17. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. Chen SL; Yan J; Wang FS J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490 [TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515 [TBL] [Abstract][Full Text] [Related]
19. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Wellington K; Jarvis B Drugs; 2002; 62(5):817-40. PubMed ID: 11929333 [TBL] [Abstract][Full Text] [Related]
20. Pimecrolimus: a review of pre-clinical and clinical data. Graham-Brown RA; Grassberger M Int J Clin Pract; 2003 May; 57(4):319-27. PubMed ID: 12800465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]